2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
3
Recruiting
2
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Leukemia, Myeloid, Acute
1
Interventions
pembrolizumab
563
Specimen Handling
493
Carboplatin
451
Magnetic Resonance Spectroscopy
444
Cyclophosphamide
418
Cisplatin
405
Radiotherapy
353
Bevacizumab
314
Gemcitabine
313
Paclitaxel
298
Biopsy
292
Drug Therapy
284
Blood Specimen Collection
248
Capecitabine
246
Oxaliplatin
241
fludarabine
239
Nivolumab
234
venetoclax
221
Injections
213
Docetaxel
211
Fluorouracil
206
Dexamethasone
188
Radiosurgery
182
Standard of Care
159
Rituximab
159
Pemetrexed
156
Surgical Procedures, Operative
148
atezolizumab
146
durvalumab
145
Leucovorin
140
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
bomedemstat
×
Clear all
NCT06351631
2026-04-02
MK-3543-017
Merck Sharp & Dohme LLC
Phase 3
Recruiting
400 enrolled
NCT05597306
2026-01-08
VenBom
University of Miami
Phase 1
Recruiting
18 enrolled